PURA - Puration Reports First Revenue From Patented Cannabis Extraction And Progress Toward $3 Million Annual Revenue Target

Dallas, Texas – May 18, 2017 -- InvestorsHub NewsWire -- – Puration, Inc. (USOTC: PURA) has published an online on demand earnings presentation reviewing the Company’s first quarter 2017 financial report.  In addition to a review of the most recent financial results, which highlights the Company’s first reported revenue from its patented cannabis extraction business, the report also includes details about the pending transaction with American Cannabis Innovations Conglomerated with specific mention that PURA stock will remain listed on the OTC Markets and will not be subject to a reverse split.  The report also includes details about the Company’s plans with NCM Biotech to pursue the development of cannabis pharmaceuticals.  Furthermore, the report includes the latest updates on the Companies three cannabis infused beverage contracts and its target $3 million in annual revenue.
 
REVIEW THE ENTIRE PURA EARNINGS REPORT
 
To learn more about Puration:                                                purationinc.com
To learn more about NCM Biotech:                                        ncmbiotech.com
 
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
 
Puration Contact:
Brian Shibley, CEO
[e-mail]
[phone]